checkAd
    SpringWorks Therapeutics Aktie
    43,35
     
    USD
    -7,45 %
    -3,49 USD
    Letzter Kurs 22:00:00 Nasdaq
    43,33
     
    USD
    200 STK
    Geldkurs 22:02:00
    43,34
     
    USD
    400 STK
    Briefkurs 22:02:00
    ISIN: US85205L1070 · WKN: A2PRLN · SYM: SWTX · USA

    Neueste Nachrichten

    SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
    12:30 Uhr · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
    18.04.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
    04.03.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
    29.02.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    27.02.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics to Present at Upcoming Investor Conferences
    22.02.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
    08.01.24 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    21.12.23 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
    29.11.23 · globenewswire · SpringWorks Therapeutics
    SpringWorks Therapeutics Announces FDA Approval of OGSIVEO (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
    28.11.23 · globenewswire · SpringWorks Therapeutics